Barrington Research Reiterates NuVasive Outperform, PT

Barrington Research reiterated its NuVasive

Outperform rating and $33 price target in a research report published today. In the report, Barrington Research states, "We are reiterating our OUTPERFORM rating and $33 price target based on the company's technology leadership, increasing revenue per procedure, growing sales bag and strong recent history of market share gains." Shares of NuVasive were trading at $17.07 at the time of posting, down 6.62% from Thursday's market close.